new day

Let's get back to the company and its markets.

Despite the suggestion that "truth is SBN is not going along beautifully ( sp anyway)", the opposite is more the reality.

Since the rights issue, SBN's SP has been well up or at least held its ground. In the same period, most specs have been massacred and heaps of the bluest blue chips are down up to 50%. The inference being that, relative to other investments, the SP has not been doing too badly.

Business-wise, though, the company is most emphatically "going along beautifully". If this is not clear, here is a reminder of the NINE recent positive announcements:

1. Issue of Quality Standard for Oraline iv and delivery of 20,000 Oraline units to China’s MPS (with up to 60,000 more to follow)

2. Successful Probeline trials and initiation of marketing

3. Agreement with Latvia Police Department

4. Expansion of SBN’s R&D department (with a new research scientist) to concentrate on the launch of Oraline VIII and ‘the development of new products in 2009 and beyond’

5. Dr Sun acquires 10m shares

6. Two directors to take up shares in lieu of Director’s fees – resulting in the whole board (and the principal scientist)having a stake in the company

7. New US distributors signed up

8. Qtr to Qtr sales increase of 70%

9. 100% take up of rights issue (remarkable in the current environment)


But that's just the start. Possible developments over the next 3 months include the following:


NOVEMBER

1. Mexico import license approval

2. Oraline order for Nuevo Leon schools testing

3. Final approvals for sales of Oraline by Top Med in Poland

4. Significant orders in Russia (perhaps including rollout in Moscow pharmacies)

5. Commencement of drug testing in Nuevo Leon schools

6. Launch of Oraline 8

7. Announcement of upgrade of the Oraline membrane production facility (to make minimum of 1,000,000 units per annum)

8. MPS preparation of instruction manuals for field testing (including preliminary testing)


DECEMBER-JANUARY

1. Relaunch of Visualine (with 2 additional drugs and lower price point)

2. Launch of Bioscreens split cup

3. UK distributorship agreement(s)

4. MPS finalisation of preliminary testing and instruction manuals for field testing in 15 cities MPS commencement of field testing in 15 cities

5. News of drug testing in schools in other Mexican States


Other possible news items, but which can’t be time estimated, include CMM’s progress with identifying required changes to Oraline to comply with Australian Standards in workplace testing, possible significant sales in Canada, and reports on outcomes of ESTHER (saliva roadside testing) meetings in Europe